Corcept Therapeutics Share Price (NASDAQ: CORT)

$70.56

▲

0.37

(0.53%)

Live

Last updated on August 21, 2025 at 1:29 AM IST

$₹

Check the interactive Corcept Therapeutics Stock chart to analyse performance

Corcept Therapeutics stock performance

as on August 21, 2025 at 1:29 AM IST

Today's Low:$70.36
Today's High:$70.83
$70.56
0.28%
Downside
Day's Volatility :0.66%
Upside
0.38%
52 Weeks Low:$33.34
52 Weeks High:$117.33
$70.56
52.75%
Downside
52 Weeks Volatility :71.58%
Upside
39.86%

Corcept Therapeutics Stock Returns

Period	Corcept Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-7.39%	1.5%	0.0%
6 Months	-4.53%	-7.1%	0.0%
1 Year	104.61%	-11.4%	0.0%
3 Years	158.56%	2.9%	-9.6%

Corcept Therapeutics Inc Key Stats

Check Corcept Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$70.19
Open	$70.54
Today's High	$70.83
Today's Low	$70.09
Market Capitalization	$7.4B
Today's Volume	$783.8K
52 Week High	$117.33
52 Week Low	$33.34
Revenue TTM	$716.1M
EBITDA	$102.6M
Earnings Per Share (EPS)	$1.12
PE Ratio	62.67
Profit Margin	18.67%
Quarterly Earnings Growth YOY	-0.09%
Return On Equity TTM	21.7%

Stock Returns calculator for Corcept Therapeutics Stock including INR - Dollar returns

The Corcept Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Corcept Therapeutics investment value today

Current value as on today

₹2,09,543

Returns

₹1,09,543

(+109.54%)

Returns from Corcept Therapeutics Stock

₹1,05,654 (+105.65%)

Dollar Returns*

₹3,889 (+3.89%)

Indian investors sentiment towards Corcept Therapeutics Stock

-2%

Period: Jul 20, 2025 to Aug 19, 2025. Change in 30 Days versus previous period

Search interest for Corcept Therapeutics Stock from India on INDmoney has decreased by -2% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Corcept Therapeutics Inc

Name
Holdings %
Name
Holdings %
BlackRock Inc
13.94%
Vanguard Group Inc
9.19%
Ingalls & Snyder LLC
7.33%
Renaissance Technologies Corp
5.83%
Parallel Advisors, LLC
3.77%
State Street Corp
3.23%

Analyst Recommendation on Corcept Therapeutics Stock

Rating

Trend

Buy

90%Buy

9%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Corcept Therapeutics(by analysts ranked 0 to 5 stars)

Corcept Therapeutics Share Price Target

What analysts predicted

Upside of 90.62%

Target:

$134.50

Current:

$70.56

Corcept Therapeutics share price target is $134.50, a slight Upside of 90.62% compared to current price of $70.56 as per analysts' prediction.

Corcept Therapeutics Stock Insights

Price Movement
In the last 1 year, CORT stock has moved up by 104.6%
Increasing Revenue
Revenue is up for the last 2 quarters, 157.21M → 194.43M (in $), with an average increase of 19.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 20.28M → 35.14M (in $), with an average increase of 42.3% per quarter

Corcept Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$306.5M	↑ 21.99%
Net Income	$94.2M	↑ 24.89%
Net Profit Margin	30.73%	↑ 0.72%

	FY20	Y/Y Change
Revenue	$353.9M	↑ 15.46%
Net Income	$106.0M	↑ 12.56%
Net Profit Margin	29.96%	↓ 0.77%

	FY21	Y/Y Change
Revenue	$366.0M	↑ 3.42%
Net Income	$112.5M	↑ 6.13%
Net Profit Margin	30.74%	↑ 0.78%

	FY22	Y/Y Change
Revenue	$401.9M	↑ 9.8%
Net Income	$101.4M	↓ 9.86%
Net Profit Margin	25.24%	↓ 5.5%

	FY23	Y/Y Change
Revenue	$482.4M	↑ 20.04%
Net Income	$106.1M	↑ 4.66%
Net Profit Margin	22.0%	↓ 3.24%

	FY24	Y/Y Change
Revenue	$675.0M	↑ 39.94%
Net Income	$139.7M	↑ 31.65%
Net Profit Margin	20.7%	↓ 1.3%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$146.8M	↑ 8.42%
Net Income	$27.8M	↓ 11.46%
Net Profit Margin	18.91%	↓ 4.25%

	Q2 FY24	Q/Q Change
Revenue	$163.8M	↑ 11.57%
Net Income	$35.5M	↑ 27.83%
Net Profit Margin	21.67%	↑ 2.76%

	Q3 FY24	Q/Q Change
Revenue	$182.5M	↑ 11.45%
Net Income	$46.7M	↑ 31.57%
Net Profit Margin	25.58%	↑ 3.91%

	Q4 FY24	Q/Q Change
Revenue	$181.9M	↓ 0.36%
Net Income	$30.4M	↓ 34.91%
Net Profit Margin	16.71%	↓ 8.87%

	Q1 FY25	Q/Q Change
Revenue	$157.2M	↓ 13.57%
Net Income	$20.3M	↓ 33.24%
Net Profit Margin	12.9%	↓ 3.81%

	Q2 FY25	Q/Q Change
Revenue	$194.4M	↑ 23.67%
Net Income	$35.1M	↑ 73.25%
Net Profit Margin	18.08%	↑ 5.18%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$301.0M	↑ 22.33%

	FY20	Y/Y Change
Profit	$348.3M	↑ 15.72%

	FY21	Y/Y Change
Profit	$360.7M	↑ 3.56%

	FY22	Y/Y Change
Profit	$396.5M	↑ 9.92%

	FY23	Y/Y Change
Profit	$475.9M	↑ 20.03%

	FY24	Y/Y Change
Profit	$664.2M	↑ 39.56%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$144.3M	↑ 8.05%

	Q2 FY24	Q/Q Change
Profit	$161.3M	↑ 11.78%

	Q3 FY24	Q/Q Change
Profit	$179.7M	↑ 11.41%

	Q4 FY24	Q/Q Change
Profit	$178.9M	↓ 0.41%

	Q1 FY25	Q/Q Change
Profit	$154.8M	↓ 13.48%

	Q2 FY25	Q/Q Change
Profit	$191.0M	↑ 23.37%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$136.1M	↑ 17.68%
Investing Cash Flow	$-117.8M	↑ 29.81%
Financing Cash Flow	$-28.6M	↑ 99.83%

	FY20	Y/Y Change
Operating Cash Flow	$152.0M	↑ 11.65%
Investing Cash Flow	$-119.3M	↑ 1.22%
Financing Cash Flow	$12.2M	↓ 142.64%

	FY21	Y/Y Change
Operating Cash Flow	$167.9M	↑ 10.48%
Investing Cash Flow	$136.1M	↓ 214.14%
Financing Cash Flow	$-302.6M	↓ 2577.41%

	FY22	Y/Y Change
Operating Cash Flow	$120.3M	↓ 28.33%
Investing Cash Flow	$-114.3M	↓ 183.99%
Financing Cash Flow	$-17.3M	↓ 94.29%

	FY23	Y/Y Change
Operating Cash Flow	$127.0M	↑ 5.58%
Investing Cash Flow	$90.9M	↓ 179.51%
Financing Cash Flow	$-148.7M	↑ 760.47%

	FY24	Y/Y Change
Operating Cash Flow	$198.1M	↑ 55.91%
Investing Cash Flow	$-177.6M	↓ 295.37%
Financing Cash Flow	$-28.3M	↓ 80.94%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$23.8M	↑ 303.53%
Investing Cash Flow	$-9.0M	↓ 152.72%
Financing Cash Flow	$-543.0K	↓ 170.89%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$41.2M	↑ 73.35%
Investing Cash Flow	$-60.2M	↑ 567.78%
Financing Cash Flow	$-2.2M	↑ 295.95%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$73.8M	↑ 79.27%
Investing Cash Flow	$-44.0M	↓ 26.84%
Financing Cash Flow	$-21.1M	↑ 881.02%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$59.3M	↓ 19.68%
Investing Cash Flow	$-64.4M	↑ 46.15%
Financing Cash Flow	$-4.6M	↓ 78.36%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$5.1M	↓ 91.35%
Investing Cash Flow	$-3.2M	↓ 95.07%
Financing Cash Flow	$-39.8M	↑ 772.11%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$43.9M	↑ 756.84%
Investing Cash Flow	$70.1M	↓ 2311.51%
Financing Cash Flow	$-102.9M	↑ 158.61%

Corcept Therapeutics Technicals Summary

Sell

Neutral

Buy

Corcept Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Corcept Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Corcept Therapeutics Inc	0.11%	-4.53%	104.61%	158.56%	443.55%
Regeneron Pharmaceuticals, Inc.	4.65%	-16.73%	-52.11%	-6.73%	-5.71%
Beone Medicines Ltd	7.16%	32.17%	61.08%	80.84%	30.07%
Vertex Pharmaceuticals Incorporated	-14.79%	-17.19%	-19.84%	32.96%	44.01%
Alnylam Pharmaceuticals, Inc.	43.03%	83.01%	63.29%	110.39%	235.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Corcept Therapeutics Inc	62.67	62.67	0.61	1.08	0.22	0.08	NA	6.04
Regeneron Pharmaceuticals, Inc.	14.47	14.47	1.18	39.36	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.73	27.73	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Corcept Therapeutics Inc	Buy	$7.4B	443.55%	62.67	18.67%
Regeneron Pharmaceuticals, Inc.	Buy	$60.8B	-5.71%	14.47	31.37%
Beone Medicines Ltd	NA	$39.3B	30.07%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.0B	44.01%	27.73	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.8B	235.62%	NA	-12.96%

About Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Organization	Corcept Therapeutics
Employees	500
CEO	Dr. Joseph K. Belanoff M.D.
Industry	Health Technology

Key Management of Corcept Therapeutics Inc

Name	Title
Dr. Joseph K. Belanoff M.D.	Co-Founder, President, CEO & Director
Mr. Atabak Mokari	CFO & Treasurer
Mr. Sean Maduck	President of Endocrinology
Dr. William Guyer Pharm.D.	Chief Development Officer
Mr. Gary Charles Robb J.D.	Chief Business Officer & Secretary
Mr. Joseph Douglas Lyon	Chief Accounting & Technology Officer
Dr. Hazel Hunt Ph.D.	Chief Scientific Officer
Ms. Amy Flood	Chief Human Resources & Communications Officer
Ms. Monica Tellado	President of Emerging Markets
Mr. Roberto W. Vieira	President of Oncology

Important FAQs about investing in CORT Stock from India :

What is Corcept Therapeutics share price today?

Corcept Therapeutics share price today is $70.56 as on August 21, 2025 at 1:29 AM IST. Corcept Therapeutics share today touched a day high of $70.83 and a low of $70.36.

What is the 52 week high and 52 week low for Corcept Therapeutics share?

Corcept Therapeutics share touched a 52 week high of $117.33 and a 52 week low of $33.34. Corcept Therapeutics stock price today i.e. August 21, 2025 at 1:29 AM IST is trending at $70.56, lower by 39.86% versus the 52 week high.

How to invest in Corcept Therapeutics Stock (CORT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Corcept Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Corcept Therapeutics Shares that will get you 0.0213 shares as per Corcept Therapeutics share price of $70.56 per share as on August 21, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Corcept Therapeutics Stock (CORT) from India?

Indian investors can start investing in Corcept Therapeutics (CORT) shares with as little as ₹87.0225 or $1 (as of August 20, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹870.22 in Corcept Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 20, 2025). Based on Corcept Therapeutics share’s latest price of $70.56 as on August 21, 2025 at 1:29 AM IST, you will get 0.1417 shares of Corcept Therapeutics. Learn more about fractional shares .

What are the returns that Corcept Therapeutics has given to Indian investors in the last 5 years?

Corcept Therapeutics stock has given 443.55% share price returns and 16.26% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?